Vera Therapeutics stock rocketed nearly 70% on Monday on upbeat data for a kidney-disease trial. Shares are tumbling Friday ...

Shares of the biotech Kymera Therapeutics are up 50% since Monday, when data from an early trial hinted that its pill might ...

For investors still seeking companiies with attractive long-term prospects, let's consider two in the biotech industry: ...

Forget the hyper-volatile, high-profile stock names. In this environment, lesser-known and less-exciting stocks are apt to ...

Any point can be considered low -- even after massive gains -- provided there is plenty of upside left. That brings us to ...

Discover why NNNN's pivot to oncology and other assays faces challenges as COVID-related revenues decline, with valuation ...

Regencell's stock soared 17,000% fueled by speculation, despite no revenue or clinical progress. Read why I think the RGC ...

French drugmaker Sanofi said Monday it has agreed to acquire Blueprint Medicines for $9.5 billion, sending shares of the ...

MAIA’s Chairman and CEO Vlad Vitoc, M.D., expressed optimism regarding the results, stating, "This new benchmark of 17.8 months median OS is nearly triple the recognized SOC data for third-line NSCLC ...

Ailsa Craig and Marek Poszepczynski, portfolio managers at the International Biotechnology Trust, tell MoneyWeek where they’d ...

Intellia Therapeutics’ stock may have taken a hit in the wake of details of a grade 4 adverse event in a phase 3 trial, but ...

Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported ...